

62th ASH Annual Meeting

13 études en Oral Poster Session

Dont 3 en 1er/dernier auteur

143 – Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Type: Oral

Aurore Perrot, MD, PhD, Valerie Lauwers-Cances², Titouan Cazaubiel³, Thierry Facon, MD⁴, Denis Caillot⁵, Lauriane Clement-Filliatre⁶, Margaret Macro⁷, Olivier Decaux⁸, Karim Belhadj, MD⁹, Mohamad Mohty¹⁰, Lionel Karlin, MD¹¹, Jean Claude Eisenmann¹², Mourad Tiab¹³, Frederique Orsini¹⁴, Cyrille Touzeau¹⁵, Xavier Leleu, MD¹⁶, **Herve Avet-Loiseau**, Nikhil C. Munshi, MD¹⁸, Kenneth Anderson, MD¹⁹, Paul G. Richardson, MD²⁰, Philippe Moreau²¹ and **Michel Attal**²

<https://ash.confex.com/ash/2020/webprogram/Paper134538.html>

603 – The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Type: Oral

Titouan Cazaubiel¹, Laure Buisson², Sabrina Maheo³, Laura Do Souto Ferreira⁴, Romain Lannes, PhD⁵, Aurore Perrot, MD, PhD⁶, Cyrille Hulin, MD⁷, **Hervé Avet-Loiseau**, MD, PhD and Jill Corre, PharmD, PhD⁸

<https://ash.confex.com/ash/2020/webprogram/Paper139340.html>

61 – High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Type: Oral

Mehmet K. Samur, PhD, Marco Roncador, MD, MSc¹, Anil Aktas-Samur, PhD^{2,4}, Mariateresa Fulciniti, PhD³, Abdul Hamid Bazarbachi, MD⁵, Raphael Szalat⁶, Masood A. Shammas, PhD^{8,9}, Adam S Sperlina, MD, PhD^{10,11}, Paul G. Richardson, MD^{12,13}, Florence Magrangeas¹⁴, Stephane Minvielle, PhD^{14,15}, Anjan Thakurta¹⁶, **Aurore Perrot, MD, PhD**¹⁷, **Jill Corre, PharmD, PhD**¹⁸, Philippe Moreau¹⁹, Kenneth Anderson, MD⁵, Giovanni Parmigiani, PhD^{20,21}, **Herve Avet-Loiseau**²² and Nikhil C. Munshi, MD^{23,24}

<https://ash.confex.com/ash/2020/webprogram/Paper139014.html>

57 – Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Type: Oral

Rosalinda Termini¹, Evangelos Terpos, MD, PhD², Albert Pérez, MD³, Tomas Jelinek⁴, Nikoletta-Aikaterini Kokkali⁵, Joan Bargay, MD⁶, Fernando Solano Ramos, MD, PhD⁷, Sara Rodríguez, PhD⁸, Cristina Pérez Ruiz⁹, Catarina Maia¹, Antonio Sacco, RN⁶, Marco Chiarini, MSc¹⁰, Viviana Giustini, MSc¹¹, Jill Corre, PharmD, PhD¹², Francois Vergez, DVM, PhD¹³, Marc S. Raab, MD¹⁴, Niels Weinhold, PhD¹⁵, Aitziber Lopez Lopez¹, Sonia Garate¹⁶, Diego Alignani, PhD¹, Sarvide Sarai¹, Remco Loos¹⁰, Antoni Garcia-Guiñón, MD¹⁷, Maialen Sirvent¹⁸, José Enrique de la Puerta¹⁹, Rebeca Iglesias²⁰, Maria Casanova, MD²¹, Maria Elena Cabezudo²², Valentin Cabañas, MD²³, Enrique M. Ocio, MD, PhD^{24,25}, Joaquin Martinez-Lopez, MD²⁶, Javier de la Rubia²⁷, Artur Paiva²⁸, Helena Vitoria²⁹, Catarina Geraldes, MD, PhD²⁸, Roman Hajek, MD³⁰, Heinz Ludwig, MD³¹, Hartmut Goldschmidt, MD³², **Herve Avet-Loiseau**³³, Aldo M. Roccaro, MD, PhD³³, Jesús F. San-Miguel³⁴ and Bruno Paiva, PhD³⁵

<https://ash.confex.com/ash/2020/webprogram/Paper136251.html>

58 – High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Type: Oral

Anil Aktas-Samur, PhD^{1,2}, Mariateresa Fulciniti, PhD³, Sanika Derebail, MS⁴, Raphael Szalat⁵, Giovanni Parmigiani, PhD^{6,7}, Jill Corre, PharmD, PhD⁸, Herve Avet-Loiseau^{9,10}, Mehmet K. Samur, PhD^{11,12} and Nikhil C. Munshi, MD^{13,14}
<https://ash.confex.com/ash/2020/webprogram/Paper139066.html>

422 – Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program

Type: Oral

Florent Malard, MD, PhD¹, Michael Loschi, MD, PhD², Faezeh Legrand, MD³, Raynier Devillier⁴, Sarah Guenounou, MD⁵, Cecile Borel, MD⁶, Deborah Desmier, MD⁷, Jérôme Cornillon, MD⁷, Amandine Le Bourgeois, MD⁸, Jean-Baptiste Mear, MD⁹, Delphine Martineau, MD¹⁰, Hélène Labussière, MD¹¹, Marie-Anne Couturier, MD¹², Claude-Eric Bulabois, MD¹³, Emilie Plantamura, PhD, PharmD¹⁴ and Mohamad Mohty, MD, PhD¹⁵
<https://ash.confex.com/ash/2020/webprogram/Paper136604.html>

625 – Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant *IDH1* AML: Results from Matched Comparisons to Historical Controls

Type: Oral

Peter Paschka, MD¹, Hervé Dombret, MD², Xavier Thomas, MD, PhD³, Christian Recher, MD, PhD⁴, Sylvain Chantepie, MD⁵, Pau Montesinos Fernandez, MD, PhD^{6,7}, Evelyn Acuña-Cruz, MD⁸, Paresh Vyas, MRCP, FRCPath⁹, Karl-Anton Kreuzer, MD¹⁰, Michael Heuser¹⁰, Klaus H. Metzeler, MD¹¹, Michael Dennis, MD¹², Bruno Quesnel, MD, PhD¹³, Hunault-Berger Mathilde, MD, PhD¹⁴, Mohamad Mohty, MD, PhD¹⁵, Arnaud Pigneux, MD, PhD¹⁶, Stephane De Botton, MD, PhD¹⁷, Daniela Weber, MSc¹⁸, Konstanze Dohner, MD¹⁹, Gary Milkovich, PharmD¹⁹, John Reitan, PharmD¹⁹, Sarah C. MacDonald, SD²⁰, Deborah Casso, MPH²¹, Michael Storm, MSc²², Hua Liu, PhD²², Stephanie M. Kapsalis, BS²², Eyal C. Attar, MD²², Thomas Winkler, MD²³ and Hartmut Döhner, MD²⁴
<https://ash.confex.com/ash/2020/webprogram/Paper136957.html>

39 – Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Type: Oral

Emmanuel Bachy, MD, PhD¹, Vincent Camus², Catherine Thieblemont, MD, PhD³, Rene-Olivier Casasnovas, MD⁴, Loïc Ysebaert, MD, PhD⁵, Gandhi Laurent Damaj, MD, PhD⁶, Stephanie Guidez⁷, Gian-Matteo Pica, MD⁸, Won Seog Kim, MD, PhD⁹, Soon Thye Lim, MBBS, MRCP, FAMS¹⁰, Marc André, MD¹¹, Alejandro Martin Garcia-Sancho, MD, PhD¹², Maria Jesus Penarrubia Ponce, MD¹³, Philipp B. Staber, MD, PhD¹⁴, Judith Trotman, FRACP¹⁵, Andreas Hüttmann, MD¹⁶, Vittorio Stefoni, MD, PhD¹⁷, Alessandro Re, MD¹⁸, Philippe Gaulard, MD, PhD¹⁹, Marie-Helene Delfau-Larue, MD, PhD²⁰, Laurence De Leval, MD²¹, Michel Meignan, MD²², Ju Li, PhD²³, Franck Morschhauser, MD, PhD²⁴ and Richard Delarue, MD^{25,26}
<https://ash.confex.com/ash/2020/webprogram/Paper134440.html>

120 – Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Type: Oral

Mary B. Callanan, PhD¹, Elizabeth Macintyre, PhD, MD², Marie-Helene Delfau-Larue, MD, PhD^{3,4}, Catherine Thieblemont, MD, PhD⁵, Lucie Oberic, MD^{6,7}, Emmanuel Gyan, MD, PhD⁸, Krimo Bouabdallah, MD⁹, Rémy Gressin,

MD¹⁰, Gandhi Damaj, MD, PhD¹¹, Olivier Casasnovas, MD¹², Vincent Ribrag, MD¹³, Samuel Griolet¹⁴, Bénédicte Burlet¹⁵, Benjamin Tournier, Ph.D¹⁶, Sylviane Ragot, M.Sc¹⁷, Caroline Bodet-Milin¹⁸, Olivier Hermine^{19,20} and Steven Le Guill, MD, PhD²¹
<https://ash.confex.com/ash/2020/webprogram/Paper140457.html>

422– Successful and Safe Treatment of Intestinal Graft–Versus–Host Disease (GvHD) with Pooled–Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient–Cohort of a Compassionate Use/Expanded Access Treatment Program

Type: Oral

Florent Malard, MD, PhD¹, Michael Loschi, MD, PhD², Faezeh Legrand, MD³, Raynier Devillier⁴, **Sarah Guenounou, MD⁵**, **Cecile Borel, MD⁶**, Deborah Desmier, MD⁷, Jérôme Cornillon, MD⁸, Amandine Le Bourgeois, MD⁹, Jean–Baptiste Mear, MD¹⁰, Delphine Martineau, MD¹¹, Hélène Labussière, MD¹², Marie–Anne Couturier, MD¹³, Claude–Eric Bulabois, MD¹⁴, Emilie Plantamura, PhD, PharmD¹⁵ and Mohamad Mohty, MD, PhD¹⁶
<https://ash.confex.com/ash/2020/webprogram/Paper136604.html>

36 – Large–Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and *De Novo* Diffuse Large B–Cell Lymphoma: A French Study from the Filo Group

Type: Oral

Romain Morizot¹, Sebastien Hergalant², Romain Piucco³, Florian Bouclet⁴, Anne Quinquenel, MD, PhD⁵, Caroline Dartigeas, MD⁶, Hélène Augé⁷, Eugen Tausch, MD⁸, Sandra Lomazzi⁹, Hélène Busby, MD¹⁰, Cécile Tomowiak, MD¹¹, Veronique Leblond, MD, PhD¹², Catherine Thieblemont, MD, PhD¹³, Florence Cymbalista, MD, PhD¹⁴, Marie C Bene, PharmD, DPhil¹⁵, Stephan Stilgenbauer, MD¹⁶, Romain Guieze, MD¹⁷, **Christine Carapito, PhD¹⁸**, **Aurore Perrot, MD, PhD¹⁹**, Luc Mathieu Fornecker, MD, PhD²⁰, Pierre Feugier, MD, PhD²¹ and **Julien Broséus, Dr²²**
<https://ash.confex.com/ash/2020/webprogram/Paper137061.html>

589 – Delays in Time to Deterioration of Health–Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low–Dose Cytarabine

Type: Oral

Keith W. Pratz, MD¹, Panayiotis Panayiotidis, MD², **Christian Recher, MD, PhD³**, Xudong Wei, PhD⁴, Brian A Jonas, MD, PhD, FACP⁵, Pau Montesinos, MD, PhD^{6,7}, Vladimir Ivanov⁸, Andre C. Schuh⁹, Courtney D. Dinardo, MD, MSc¹⁰, Jan Novak¹¹, Vlatko Pejisa, MD, PhD¹², Don A. Stevens, MD¹³, Su–Peng Yeh, MD¹⁴, Inho Kim, MD, PhD¹⁵, Mehmet Turgut, MD¹⁶, Nicola Fracchiolla¹⁷, Kazuhito Yamamoto, MD, PhD¹⁸, Yishai Ofran, MD¹⁹, Andrew H Wei, MBBS, PhD²⁰, Cat Bui²¹, Katy Benjamin²², Rajesh Kamalakar, MS²³, Jalaja Potluri, MD²⁴, Wellington Mendes²⁵, Jacob Devine²⁶ and Walter Fiedler, MD²⁷
<https://ash.confex.com/ash/2020/webprogram/Paper133912.html>

331 – Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Type: Oral

Ibrahim Aldoss, MD¹, Geoffrey L Uy, MD², Norbert Vey, MD³, Ashkan Emadi, M.D., Ph.D.⁴, Peter H. Sayre, MD, PhD⁵, Roland B. Walter, MD, PhD, MS⁶, Matthew C Foster, MD⁷, Martha L. Arellano, MD⁸, John E. Godwin, MD⁹, Matthew J. Wieduwilt, MD, PhD¹⁰, Michael T. Byrne, DO¹¹, Laura C. Michaelis, MD¹², Patrick J. Stiff, MD¹³, Matteo Giovanni Carrabba, MD¹⁴, Patrice Chevalier, MD, PhD¹⁵, Emmanuel Gyan, MD, PhD¹⁶, **Christian Recher, MD, PhD¹⁷**, Anjali S Advani, MD¹⁸, Martin Wermke¹⁹, Harry P. Erba²⁰, Fabio Ciceri, MD²¹, Geert Huls, MD, PhD²², Mojca Jongen–Lavrencic, MD, PhD²³, Max S. Topp, MD²⁴, Antonio Curti, MD PhD²⁵, Farhad Ravandi, MBBS²⁶, Michael P. Rettig, PhD²⁷, John Muth, MS²⁸, Mary Beth Collins²⁹, Erin Timmeny³⁰, Kuo Guo, MSc³¹, Jian Zhao, PhD³², Kathy Tran³³, Patrick Kaminker, PhD³⁴, Priyanka Patel,

PharmD²⁹, Ouiam Bakkacha, MD³³, Teia Curtis²⁴, Kenneth Jacobs, MD³⁵, Maya Kostova, PhD³¹, Jennifer Seiler, PhD, RAC²⁹, Bob Lowenberg, MD, PhD³⁶, Sergio Rutella, MD, PhD, FRCPath³⁷, Ezio Bonvini, MD³², Jan K Davidson-Moncada, MD, PhD³⁸ and John F. DiPersio, MD³
<https://ash.confex.com/ash/2020/webprogram/Paper134576.html>

34 études en Abstract Poster Sessions

dont 4 en 1er/dernier auteur, 2 en co-dernier auteur

3156 – Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

Marina Zajec¹, Pieter Langerhorst², Somayya Noori³, Martijn van Duijn⁴, Yolanda de Rijke⁵, Jolein Gloerich⁶, Alain van Gool⁷, Jill Corre, PharmD, PhD⁸, Thomas Dejoie⁹, Helene Caillon¹⁰, Joannes Jacobs¹¹, Theo Luider¹² and Herve Avet-Loiseau¹³
<https://ash.confex.com/ash/2020/webprogram/Paper139330.html>

1338 – The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Anaïs Schavgouldize¹, Valerie Lauwers-Cances², Aurore Perrot, MD, PhD³, Herve Avet-Loiseau⁴ and Jill Corre, PharmD, PhD⁵
<https://ash.confex.com/ash/2020/webprogram/Paper136996.html>

2276 – Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study

Shaji K. Kumar, MD¹, Thierry Facon, MD², Saad Z. Usmani, MD, MBBS, MBA³, Torben Plesner, MD, DSc⁴, Robert Z. Orlowski, MD, PhD⁵, Cyrille Touzeau⁶, Supratik Basu⁷, Nizar Bahlis, MD⁸, Hartmut Goldschmidt, MD⁹, Michael O'Dwyer, MD¹⁰, Christopher P. Verner, MD¹¹, Katja Weisel, MD¹², Cyrille Hulin, MD¹³, Lionel Karlin, MD¹⁴, Meir Preis, MD, PhD¹⁵, Annemiek Broyl, MD, PhD¹⁶, William Renwick¹⁷, Markus Hansson, MD¹⁸, Maria Krevvata, PhD¹⁹, Jianping Wang²⁰, Rian Van Rampelbergh²¹, Jon Ukropec, PhD²², Clarissa M. Uhlar²³, Rachel Kobos, MD²⁴ and Aurore Perrot, MD, PhD²⁵
<https://ash.confex.com/ash/2020/webprogram/Paper134847.html>

2830 – Adjunction of a Fish Oil Emulsion to Cytarabine and Daunorubicin Induction Chemotherapy in High-Risk AML. the Family Pilot Study from the French Innovative Leukemia Organization (FILO)

Emmanuel Gyan, MD, PhD¹, Arnaud Pigneux, MD, PhD², Hunault-Berger Mathilde, MD, PhD³, Pierre Peterlin, MD⁴, Martin Carre, MD⁵, Jacques-Olivier Bay, MD, PhD⁶, Caroline Bonmati, MD⁷, Maria Pilar Gallego Hernandez⁸, Bruno Lioure, MD⁹, Philippe Bertrand, MD, PhD¹⁰, Nicolas Vallet, MD¹¹, David Ternant, PharmD, PhD¹², François Darrouzain, PharmD, PhD¹³, Frederic Picou, PhD¹⁴, Marie C Bene, PharmSci, PhD¹⁵, Christian Recher, MD, PhD¹⁶ and Olivier Herault, MD, PhD¹⁷
<https://ash.confex.com/ash/2020/webprogram/Paper137210.html>

1510 – Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study

*Thomas Chalopin¹, Nicolas Vallet, MD¹, Marlene Ochmann, MD², Mourad Tiab³, Pascal Godmer⁴, Carole Barin⁵, Olivier Theisen, MD⁶, Olivier Herault, MD, PhD⁷, Emmanuel Gyan, MD, PhD^{1,7}, Lotfi Benboubker, MD¹, Philippe Moreau^{8,10}, **Herve Avet-Loiseau^{9,12,13}** and Cyrille Touzeau^{9,12,13}*
<https://ash.confex.com/ash/2020/webprogram/Paper139436.html>

1413 – Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study

*Enrique M. Ocio, MD, PhD¹, **Aurore Perrot, MD, PhD²**, Pierre Bories, MD³, Jesus F. San-Miguel, MD, PhD⁴, Igor W Blau, MD, PhD⁵, Lionel Karlin, MD⁶, Joaquin Martinez-Lopez, MD, PhD⁷, Wolfram Pönisch, MD⁸, Sara Bringhen, MD⁹, Fabio Ciceri, MD¹⁰, María-Victoria Mateos, MD, PhD¹¹, Paula Rodriguez-Otero¹², Nadia Le Roux^{12,13}, Yvonne Dong¹⁴, Thomas Fitzmaurice, PhD¹⁵, Corina Oprea, MD¹⁶ and Philippe Moreau¹⁷*
<https://ash.confex.com/ash/2020/webprogram/Paper136569.html>

2814 – AGILE: Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia and an *IDH1* Mutation

*Pau Montesinos, MD, PhD^{1,2}, **Christian Recher, MD, PhD^{3,4}**, Ewa Zarzycka, MD⁵, Vadim Doronin, MD, PhD⁶, Derek McCulloch, MB, ChB, PhD⁷, Susana Vives, MD⁸, Rodrigo T. Calado, MD, PhD⁹, Jun-Ho Jang, MD¹⁰, Yasushi Miyazaki, MD, PhD¹¹, Jianxiang Wang, MD¹², Diego A. Gianolio, PhD¹³, Scott R. Daigle, MSc¹⁴, Thomas Winkler, MD¹⁵, Vickie Zhang, PhD¹⁶ and Peter Paschka, MD¹⁷*
<https://ash.confex.com/ash/2020/webprogram/Paper136987.html>

2857 – Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

*Norbert Vey, MD¹, Corentin Orvain, MD, PhD², **Christian Recher, MD, PhD³**, Arnaud Pigneux, MD, PhD⁴, Marc Bernard, MD⁵, Anne Banos, MD⁶, Pierre Peterlin, MD⁷, Sylvain Chantepie, MD⁸, Xavier Thomas, MD, PhD⁹, Cecile Pautas, MD^{10,11}, Claude Gardin¹², Emilie Lemasle, MD¹³, Emmanuel Raffoux, MD¹⁴, Romain Guieze, MD¹⁵, Chantal Hemberlin, MD¹⁶, Clémence Loiseau, MD¹⁷, Amine Belhabri, MD¹⁸, Isabelle Luquet, MD¹⁹, Christine Terré, PharmD, PhD²⁰, Martin Carre, MD²¹, Claude Preudhomme, MD, PhD²², Eric Delabesse, MD, PhD²³, Karine Celli-Lebras, CRA²⁴, Ariane C Mineur, CRA²⁵, Jean-Francois Brasme, MD, PhD²⁶, Jean Francois Hamel, MD²⁶, Hervé Dombret, MD²⁷ and Mathilde Hunault, MD PhD^{28,29}*
<https://ash.confex.com/ash/2020/webprogram/Paper137032.html>

931 – Impact and Dynamics of *TP53* Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients

*Jean-Alain Martignoles¹, Pierre Hirsch, MD, PhD², Blandine Beaupain³, Thomas Longval, MD⁴, Nawa Hachem, MSc⁵, Mira El-Khoury, PhD⁶, Sophie Kaltenbach⁷, Jean Soulier, MD, PhD⁸, Thierry Leblanc, M.D.^{9,10}, Pierre Simon Rohrllich, MD PhD¹¹, Eric Jeziorski, MD PhD¹², Isabelle Meyts¹³, Dalila Adjaoud, MD¹⁴, Vincent Barlogis, M.D., Ph.D.¹⁵, Marlène Pasquet, M.D., Ph.D.¹⁶, **Laetitia Largeaud¹⁷**, Flore Sicre de Fontbrune¹⁸, Claire Fieschi, MD, PhD¹⁹, Virginie Gandemer, MD, PhD²⁰, Nathalie Aladjidi, MD²¹, Fanny Fouyssac, MD²², Guy Leverger, M.D.²³, Wadih Abou Chahla, M.D.²⁴, Stephane Blanche, MD²⁵, Despina Moushous, MD, PhD²⁶, Aline Moignet Autrel, MD²⁷, Yves Bertrand, M.D.^{28,29}, Cecile Renard^{29,30}, Pascale Flandrin-Gresta, MD^{31,32}, Jean Louis Stephan, MD PhD³³, Olivier Tournilhac, MD, PhD^{34,35}, Liana Carausu³⁶, Frederic Millot, M.D.³⁷, Marielaure Couec, MD³⁸, Claude Preudhomme, MD, PhD^{39,40,41,42}, Héléne Lapillonne, MD, PhD⁴³, Vahid Asnafi, MD, PhD^{44,45,46}, Patrick Revy⁴⁷, Christine Bellanne-Chantelot, PhD, PharmD^{48,49}, Francois Delhommeau, MD, PhD⁵⁰ and Jean Donadieu, MD, PhD¹*

<https://ash.confex.com/ash/2020/webprogram/Paper138540.html>

2817 – Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

*Geoffrey L Uy, MD, Michael P. Rettig, PhD², Stephanie Christ, MS³, Ibrahim Aldoss, MD, Michael T. Byrne, DO⁵, Harry P. Erba, MD, PhD⁶, Martha L. Arellano, MD⁷, Matthew C Foster, MD⁸, John E. Godwin, MD⁹, Farhad Ravandi, MBBS¹⁰, Peter H. Sayre, MD, PhD¹¹, Anjali S Advani, MD¹², Matthew J. Wieduwilt, MD, PhD¹³, Ashkan Emadi, M.D., Ph.D.¹⁴, Laura C. Michaelis, MD¹⁵, Patrick J. Stiff, MD¹⁶, Martin Wermke¹⁷, Norbert Vey, MD¹⁸, Patrice Chevalier, MD, PhD¹⁹, Emmanuel Gyan, MD, PhD²⁰, **Christian Recher, MD, PhD²¹**, Fabio Ciceri, MD²², Matteo Giovanni Carrabba, MD²³, Antonio Curti, MD PhD²⁴, Geert Huls, MD, PhD²⁵, Max S. Topp, MD²⁶, Mojca Jongen-Lavrencic, MD, PhD²⁷, John Muth, MS²⁸, Teia Curtis²⁹, Mary Beth Collins³⁰, Erin Timmeny³¹, Kuo Guo, MSc³², Jian Zhao, PhD³², Kathy Tran³³, Patrick Kaminker, PhD³³, Priyanka Patel, PharmD³⁰, Ouliam Bakkacha, MD³⁴, Kenneth Jacobs, MD³⁵, Maya Kostova, PhD³⁵, Jennifer Seiler, PhD, RAC³⁰, Bob Lowenberg, MD, PhD³⁶, Sergio Rutella, MD, PhD, FRCPath³⁷, Roland B. Walter, MD, PhD, MS³⁸, Ezio Bonvini, MD³³, Jan K Davidson-Moncada, MD, PhD³⁹ and John F. DiPersio, MD*

<https://ash.confex.com/ash/2020/webprogram/Paper134612.html>

2878 – Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

*Jayakumar Vadakekolathu, PhD¹, Tung On Yau¹, Sarah E. Church, PhD², Michael P. Rettig, PhD³, Ibrahim Aldoss, M.D.⁴, Geoffrey L Uy, MD⁵, Norbert Vey, MD⁶, Ashkan Emadi, M.D., Ph.D.⁷, Peter H. Sayre, MD, PhD⁸, Roland B. Walter, MD, PhD, MS⁹, Matthew C Foster, MD¹⁰, Martha L. Arellano, MD¹¹, John E. Godwin, MD¹², Matthew J. Wieduwilt, MD, PhD¹³, Michael T. Byrne, DO¹⁴, Laura C. Michaelis, MD¹⁵, Patrick J. Stiff, MD¹⁶, Matteo Giovanni Carrabba, MD¹⁷, Patrice Chevalier, MD, PhD¹⁸, Emmanuel Gyan, MD, PhD¹⁹, **Christian Recher, MD, PhD²⁰**, Anjali S Advani, MD²¹, Martin Wermke²², Harry P. Erba²³, Fabio Ciceri, MD²⁴, Geert Huls, MD, PhD²⁵, Mojca Jongen-Lavrencic, MD, PhD²⁶, Farhad Ravandi, MBBS²⁷, Antonio Curti, MD PhD²⁸, Max S. Topp, MD²⁹, John Muth, MS³⁰, Patrick Kaminker, PhD³⁰, Bob Lowenberg, MD, PhD³¹, Ivana Gojo, MD³², Leo Luznik, MD³², John F. DiPersio, MD³, Jan K Davidson-Moncada, MD, PhD³⁰ and Sergio Rutella, MD, PhD, FRCPath^{1,33}*

<https://ash.confex.com/ash/2020/webprogram/Paper134921.html>

2069 – Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups

*Amira Marouf², Anne Ségolène Cottereau, MD³, Guillemette Fouquet, MD⁴, Salim Kanoun, MD⁵, Patricia Franchi, MD⁶, Romain Ricci⁷, Michel Meignan, MD⁸, David Sibon, MD, PhD⁹, Thomas Gastinne, MD¹⁰, **Cecile Borel, MD¹¹**, Mohammad Hammoud, MD¹², Guillaume Sicard, MD¹³, Romane Gille¹⁴, Doriane Cavalieri, MD¹⁵, Aspasia Stamatoulas Bastard, MD¹⁶, Lauriane Clement-Filliatre, MD¹⁷, Julien Lazarovici, MD¹⁸, Adrien Chauchet, MD¹⁹, Luc Mathieu Fornecker, MD, PhD^{20,21}, Sandy Amorin, MD²², Mathieu Roquet²⁴, Nicole Raus, Data Manager²³, Rene-Olivier Casasnovas, MD^{24,25}, Guillaume Cartron, MD, PhD^{26,27}, Hervé Ghesquieres, MD, PhD²⁸, Pauline Brice, MD²⁹, Olivier Hermine^{30,31}, Didier Bouscary, MD, PhD³², Marie Thérèse Rubio, MD, PhD^{33,34}, Jerome Tamburini, MD, PhD^{35,36,37} and **Benedicte Deau Fischer^{4,6,38}***

<https://ash.confex.com/ash/2020/webprogram/Paper138666.html>

3209 – Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM)

*Niels W.C.J. Van De Donk¹, Sonja Zweegman, MD, PhD², Jesus F. San-Miguel, MD, PhD³, Meletios A Dimopoulos⁴, Michele Cavo⁵, Kenshi Suzuki, MD, PhD⁶, Cyrille Touzeau⁷, Saad Z. Usmani, MD, MBBS, MBA⁸, **Aurore Perrot, MD, PhD⁹**, Huiling Pei, PhD¹⁰, Anupa Kudva, MD¹¹, Rian Van Rampelbergh¹², Jon Ukropec, PhD¹³, Kevin Leary¹⁴, Robin Carson, MD, BA¹⁴, Ming Qi, MD, PhD¹⁴ and Ajai Chari¹⁵*

<https://ash.confex.com/ash/2020/webprogram/Paper134923.html>

1994 – IDH Mutations Identify a Subgroup of *NPM1* Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

*Sylvain Garciaz*¹, *Marie Anne Hospital*², *Colombe Saillard*, MD³, *Yosr Hicheri*⁴, *Evelyne D'Incan*², *Jerome Rey*², *Catherine Lacombe*⁵, *Arnaud Pigneux*, MD, PhD⁶, *Marie-Christine Béné*, PharmSciD, PhD⁷, *Christian Recher*, MD, PhD⁸, *Marie-Joelle Mozziconacci*⁹ and *Norbert Vey*, MD¹⁰
<https://ash.confex.com/ash/2020/webprogram/Paper141229.html>

3126 – Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a *BCL2* rearrangement

Charles Herbaux, MD, MSc, *Imelda Raczkiewicz*², *Kamel Laribi*, MD³, *Loic Ysebaert*, MD, PhD⁴, *Agnes Daudignon*⁵, *Sabine Tricot*⁶, *Aurelie Caillault-Venet*⁷, *Alain Jacques Delmer*, MD, PhD⁸, *Pascale Cornillet-Lefebvre*⁹, *Cymbalista Florence*¹⁰, *Virginie Eclache*¹¹, *Pierre Morel*, MD¹², *Gauthier Decool*⁷, *Morgane Nudel*¹³, *Romain Guieze*, MD¹⁴, *Liam Hackett*, BS¹⁵, *Stephen Jun Fei Chong*¹⁶, *Mary C Collins*, BS¹⁶, *Florence Nguyen-Khac*, MD, PhD¹⁷, *Fatiha Merabet*, MD¹⁸, *Jasmine Chauzeix*¹⁹, *Stéphanie Struski*, MD²⁰, *Jennifer R. Brown*, MD, PhD²¹, *Matthew S. Davids*, MD²¹ and *Stéphanie Poulain*, MD, PhD²²
<https://ash.confex.com/ash/2020/webprogram/Paper139210.html>

1411 – Isatuximab Plus Pomalidomide and Dexamethasone in Frail Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik Schjesvold, MD, PhD, *Sara Bringhen*, MD², *Paul G. Richardson*, MD³, *Aurore Perrot*, MD, PhD⁴, *Xavier Leleu*, MD⁵, *Philippe Moreau*⁶, *Meletios A. Dimopoulos*, MD⁷, *Cyrille Hulin*, MD⁸, *Christina Tekle*⁹, *Meredith Foster*¹⁰, *Elizabeth M Poole*¹¹, *Helgi van de Velde*, MD, PhD¹⁰ and *Thierry Facon*, MD¹²
<https://ash.confex.com/ash/2020/webprogram/Paper136369.html>

3155 – Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Abdul Hamid Bazarbachi, MD¹, *Herve Avet-Loiseau*², *Zachary R Hunter*, PhD³, *Raphael Szalat*⁴, *Anil Aktas-Samur*, PhD⁵, *Masood A. Shamma*, PhD⁶, *Jill Corre*, PharmD, PhD⁷, *Mariateresa Fulcini*, PhD⁸, *Kenneth Anderson*, MD⁹, *Giovanni Parmigiani*, PhD¹⁰, *Steven Treon*¹¹, *Mohamad Mohty*, MD, PhD^{12,13}, *Mehmet K. Samur*, PhD¹⁴ and *Nikhil C. Munshi*, MD¹⁵
<https://ash.confex.com/ash/2020/webprogram/Paper138951.html>

920 – Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

*Jean-Edouard Martin*¹, *Sabine Khalife-Hachem*¹, *Thomas Grinda*¹, *Maria Kfoury*¹, *Sylvain Garciaz*², *Florence Pasquier*, MD, PhD³, *Jacques Vargaftig*⁴, *Madalina Uzunov*, MD⁵, *Amine Belhabri*, MD⁶, *Sarah Bertoli*, MD, PhD⁷, *Nathalie Auger*⁸, *Veronique Saada*⁹, *Christel Guillouf*¹, *Iléana Antony-Debre*, PhD², *Etienne Rouleau*¹, *Flore Salviat*¹, *Olivier Caron*¹, *Patricia Pautier*¹, *Gabriel Etienne*, MD, PhD¹⁰, *Norbert Vey*, MD¹¹, *Filippo Rosselli*¹, *Stephane De Botton*, MD, PhD¹², *Alexandra Leary*¹, *Christophe Marzac*, MD¹³ and *Jean-Baptiste Micol*, MD¹⁴
<https://ash.confex.com/ash/2020/webprogram/Paper139971.html>

1214 – R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers

Vincent Camus¹, Alina Berriolo-Riedinger², Justine Lequesne³, David Tonnelet, MD⁴, Pierre Decazes⁴, Cédric Rossi, MD, PhD⁵, Pierre Sesques, MD⁶, Corinne Haioun, MD, PhD⁷, Eric Durot, MD⁸, Alexandre Willaume⁹, Martin Gauthier¹⁰, Marie-Pierre Moles, MD¹¹, Chloe Antier¹², Julien Lazarovici, MD¹³, Helene Monjanel¹⁴, Sophie Bernard¹⁵, Magalie Tardy¹⁶, Caroline Besson, MD, PhD¹⁷, Laure Lebras, MD¹⁸, Choquet Sylvain¹⁹, Katell Le Du, MD²⁰, Christophe Bonnet, MD²¹, Sarah Bailly, MD²², Damaj Gandhi Laurent, MD, PhD²³, Kamel Laribi, MD²⁴, Herve Maisonneuve, MD²⁵, Roch Houot, MD, PhD²⁶, Adrien Chauchet, MD²⁷, Fabrice Jardin, MD, PhD¹, Stephanie Becker, MD²⁸ and Herve Tilly, MD, PhD⁴

<https://ash.confex.com/ash/2020/webprogram/Paper136600.html>

3018 – First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort

Khe Hoang-Xuan, MD, PhD¹, Roch Houot, MD, PhD², Carole Soussain, MD, PhD³, Marie Blonski, MD⁴, Anna Schmitt, MD⁵, Vincent Delwail, MD⁶, Gandhi Laurent Damaj, MD, PhD⁷, Herve Ghesquieres, MD, PhD⁸, Frédéric Peyrade, MD⁹, Adrian Tempescul, MD¹⁰, Julie Abraham, MD¹¹, Philippe Agape, MD¹², Guido Ahle, MD¹³, Nathalie Baize, MD¹⁴, Pierre Bories, MD¹⁵, Chantal Campello, MD¹⁶, Emmanuel Gyan, MD, PhD¹⁷, Fabrice Jardin, MD, PhD¹⁸, Philippe Rey, MD¹⁹, Sylvain Choquet, MD²⁰, Caroline Houillier, MD²¹, Nathalie Cassoux, MD, PhD²², Valerie Toutou, MD, PhD²³, Nadine Martin-Duverneuil, MD²⁴, Frederic Legrand²⁵, Assia Lamrani-Ghaouti²⁶, Ophelie Querel²⁶, Natalie Hoog Labouret, MD²⁵, Clotilde Simon²⁶, Sylvie Chevret, MD, PhD²⁷ and Christophe Massard, MD, PhD²⁸

<https://ash.confex.com/ash/2020/webprogram/Paper141773.html>

950 – Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao¹, Woojun D Park², Eugenio Morelli, MD³, Mehmet Kemal Samur, PhD⁴, Nicholas P Kwiatkowski, PhD⁵, Yan Xu, MD⁶, Chandraditya Chakraborty, PhD⁷, Behnam Nabet, PhD⁸, Marta Chesi, PhD⁹, Herve Avet-Loiseau^{10,11}, Nathaniel Gray¹², Richard A. Young, PhD^{13,14}, Kenneth Anderson, MD^{6,15,16,17}, Charles Y Lin, PhD^{18,19}, Nikhil C. Munshi, MD^{17,20,21,22} and Mariateresa Fulciniti, PhD⁶

<https://ash.confex.com/ash/2020/webprogram/Paper142592.html>

1529 – Impact of Donor Search Strategy for Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical or Matched Unrelated Donor for Patients Older Than 55 Years with Hematological Malignancies: Randomized Prospective Phase III Study

Samia Harbi¹, Jean Marie Boher², Edouard Forcade, MD³, Patrice Chevallier, MD, PhD⁴, Peffault De Latour Régis⁵, Florent Malard, MD, PhD⁶, Sylvie Francois, MD⁷, Amandine Charbonnier, MD⁸, Eric Hermet, MD⁹, Claude-Eric Bulabois, MD¹⁰, Anne Huynh¹¹, Ana Berceanu, MD¹², Thomas Cluzeau, MD, PhD¹³, Marie Thérèse Rubio, MD, PhD¹⁴, Sabine Furst¹, Mohamad Mohty, MD, PhD¹⁵, Raynier Devillier^{16,17} and Didier Blaise, MD¹⁸

<https://ash.confex.com/ash/2020/webprogram/Paper139440.html>

2664 – Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study

Stephanie Guillet¹, Valentine Loustau², Anissa Zarour³, Emmanuelle Boutin, MD⁴, Thibault Comont⁵, Nathalie Costedoat-Chalumeau, MD, PhD⁶, Brigitte Pan-Petesht, MD⁷, Delphine Gobert, M.D⁸, Stephane Cheze, MD⁹, Odile Souchaud-Debouverie¹⁰, Jean-Francois Viillard¹¹, Anne-Sophie Morin¹², Gaetan Sauvetre¹³, Manuel Cliquennois, MD, MSc¹⁴, Bruno Royer, MD¹⁵, Corinne Haioun, MD PhD¹⁶, Agathe Masseur¹⁷, Louis Terriou¹⁸, Claire Fieschi, MD, PhD¹⁹, Matthieu Mahevas²⁰, Marc Michel²¹ and Bertrand Godeau²¹

<https://ash.confex.com/ash/2020/webprogram/Paper140329.html>

2040 – Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Michael Wang, MD, Simon Rule, MD, PhD², Pier Luigi Zinzani, MD³, Andre H. Goy, MD⁴, Rene-Olivier Casasnovas, MD⁵, Stephen D. Smith, MD⁶, Gandhi Laurent Damaj, MD, PhD⁷, Jeanette K. Doorduijn, MD, PhD⁸, Thierry Lamy⁹, Franck Morschhauser, MD, PhD¹⁰, Carlos Panizo, MD, PhD¹¹, Bijal Shah, MD¹², Andrew Davies, MD, PhD¹³, Richard Eek, FRACP¹⁴, Jehan Dupuis, MD¹⁵, Eric Jacobsen, MD¹⁶, Arnon P. Kater, MD, PhD¹⁷, Steven Le Gouill, MD, PhD¹⁸, Lucie Oberic, MD¹⁹, Tadeusz Robak, MD PhD²⁰, Preetesh Jain, MBBS, MD, DM, PhD¹, Graham Brock, PhD²¹, Priti Patel, MD²¹, Lin Tao²¹ and Monika Dlugosz-Danecka, MD, PhD²²
<https://ash.confex.com/ash/2020/webprogram/Paper134824.html>

1904 – Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with *FLT3* Mutations

Marina Konopleva, MD, PhD, Michael Thirman, MD², Keith W. Pratz, MD³, Anthony G. Letai, MD, PhD⁴, Christian Recher, MD, PhD⁵, Vinod A. Pullarkat, MD⁶, Hagop M. Kantarjian, MD⁷, Monique Dail, PhD⁸, Yinghui Duan, PhD⁹, Brenda J. Chyla⁹, Jalaja Potluri, MD⁹, Catherine Miller, PharmD⁹, Courtney D. Dinardo, MD, MSc and Andrew H. Wei, MBBS, PhD¹⁰
<https://ash.confex.com/ash/2020/webprogram/Paper134100.html>

840 – Risk Factors of Neonatal Immune Thrombocytopenia in Pregnant Women Previously Diagnosed with ITP: Results from a French Nationwide Prospective Study

Stephanie Guillet¹, Valentine Loustau², Anissa Zarour³, Emmanuelle Boutin, MD⁴, Thibault Comont⁵, Odile Souchaud-Debouverie⁶, Nathalie Costedoat-Chalumeau, MD, PhD⁷, Brigitte pan-Petesich, MD⁸, Delphine Gobert, M.D⁹, Stephane Cheze, MD¹⁰, Jean-Francois Viillard¹¹, Anne-Sophie Morin¹², Gaetan Sauvetre¹³, Manuel Cliquennois, MD, MSc¹⁴, Bruno Royer, MD¹⁵, Corinne Haioun, MD PhD¹⁶, Agathe Masseur¹⁷, Louis Terriou¹⁸, Claire Fieschi, MD, PhD¹⁹, Matthieu Mahevas²⁰, Marc Michel²¹ and Bertrand Godeau²¹
<https://ash.confex.com/ash/2020/webprogram/Paper140511.html>

1076 – Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A–Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG

Romy E. Van Weelderen^{1,2}, Kim Klein, MD^{3,4}, Bianca F. Goemans, MD, PhD⁵, Christian M. Zwaan, MD, PhD^{5,6}, Hester A. De Groot-Kruseman, PhD^{5,7}, Jonas Abrahamsson, MD, PhD⁸, Nira Arad-Cohen, MD, PhD⁹, Emmanuelle Bart-Delabesse, PharmD, PhD¹⁰, Barbara Buldini, MD, PhD¹¹, Barbara De Moerloose, MD, PhD¹², Michael Dworzak, MD, PhD¹³, Sarah Elitzur, MD¹⁴, José M. Fernández Navarro, MD¹⁵, Robert B. Gerbing, MA¹⁶, Erin Guest, MD¹⁷, Shau-Yin Ha, MD, PhD¹⁸, Christine J. Harrison, PhD, FRCPATH¹⁹, Henrik Hasle, MD²⁰, Kathy Jackson, MD, PhD²¹, Charikleia Kelaidi, MD²², H el ene Lapillonne, MD, PhD²³, Guy Leverger, MD, PhD²⁴, Franco Locatelli, MD, PhD²⁵, Takako Miyamura, MD, PhD²⁶, Sophia Polychronopoulou, MD, PhD²⁷, Mareike Rasche, MD²⁷, Jeffrey E. Rubnitz, MD²⁸, Jan Stary, MD, PhD²⁹, Daisuke Tomizawa, MD, PhD³⁰, Femke Verwer^{2,7} and Gertjan J.L. Kaspers, Prof. MD, PhD^{3,5}
<https://ash.confex.com/ash/2020/webprogram/Paper136064.html>

2317 – Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone

Jesus F. San-Miguel, MD, PhD, Herve Avet-Loiseau¹, Bruno Paiva, PhD², Shaji K. Kumar, MD³, Meletios A. Dimopoulos, MD⁴, Thierry Facon, MD⁵, Maria-Victoria Mateos, MD, PhD⁶, Cyrille Touzeau⁷, Andrzej Jakubowiak, MD, PhD⁸, Saad Z. Usmani, MD, MBBS, MBA⁹, Gordon Cook, MD¹¹, Michele Cavo¹², Hang Quach, MD, FRACP, FRCPA, MBBS¹³, Jon Ukropec, PhD¹⁴, Priya Ramaswami¹⁵, Huiling Pei, PhD¹⁵, Steven Sun¹⁶, Jianping Wang¹⁶, Maria Krevvata,

PhD¹⁷, Nikki DeAngelis¹⁷, Christoph Heuck¹⁷, Rian Van Rampelbergh¹⁸, Anupa Kudva, MD⁶, Rachel Kobos, MD¹⁶, Ming Qi, MD, PhD⁷ and Nizar Bahlis, MD¹⁹
<https://ash.confex.com/ash/2020/webprogram/Paper134928.html>

2118 – Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Christiane Copie Bergman, MD PhD¹, Elodie Bohers, PhD², Peggy Dartigues-Cuillères, MD³, Pierre-Julien Viailly⁴, Philippe Ruminy, PhD⁵, Vinciane Marchand⁶, Marie-Helene Delfau-Larue⁶, Corinne Haioun, MD PhD⁶, Cyrielle Robe⁷, Elsa Pouillot, MD⁸, Steven Le Gouill, MD, PhD⁹, Yannick Le Bris, PharmD¹⁰, Céline Bossard, MD¹¹, Anne Moreau, MD¹², Vincent Ribrag, MD¹³, Valérie Camara-clayette, PhD¹³, Cyril Quivoron, PhD¹⁴, Gilles Salles, MD, PhD¹⁵, Sophie Cotteret, MD, PhD¹⁵, Pierre Sujobert, MD, PhD¹⁶, Alexandra Traverse-Glehen, MD, PhD¹⁷, Claire Mauduit¹⁸, Pascaline Etancelin¹⁹, Sarah Huet²⁰, Liana Veresezan, MD²¹, Krimo Bouabdallah, MD²², Marie Parrens, MD²³, Audrey Gros, PhD²⁴, Samuel Amintas²⁵, David Sibon, MD, PhD²⁶, Ludovic Lhermitte, MD, PhD²⁷, Thomas Steimle²⁸, Sophie Kaltenbach²⁹, Bettina Fabiani, MD³⁰, **Camille Laurent, MD, PhD³¹**, Barbara Burroni³², Laurent Martin, MD, PhD³³, Thierry Jo Molina, MD, PhD³⁴, Lysa LYSARC study group³⁵ and **Fabrice Jardin, MD, PhD³⁶**
<https://ash.confex.com/ash/2020/webprogram/Paper141953.html>

1049 – AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone

Helal Mohammed Mohammed Ahmed Noman, MBBS, Yahya Saleh Al-Matary, PhD¹, Subbaiah Chary Nimmagadda, PhD², Maren Fiori³, Pradeep Kumar Patnana, M.Sc.³, Daria Frank³, Lanying Wei, M.Sc.³, Judith Schütte, PhD³, Tobias May⁶, Joachim R. Goethert, MD⁴, Thomas Schroeder, MD⁷, Ulrike Buttkeireit, PhD⁴, **Christian Recher, MD, PhD⁵**, Manuel Rodríguez-Paredes⁵, Thorsten Koenig¹⁰, Wolfgang Hartmann, MD¹¹, Jan Tuckermann, PhD¹², Bertram Opalka, PhD⁴, Georg Lenz³ and Cyrus Khandanpour, PD, MD³
<https://ash.confex.com/ash/2020/webprogram/Paper134177.html>

1161 – Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

Olivier Tournilhac, MD, PhD¹, Maya Hacini, MD², Kamal Bouabdallah, MD³, Kamel Laribi, MD⁴, Marie Maerevoet, MD⁵, **Loic Ysebaert, MD, PhD⁶**, Stephanie Guidez⁷, Steven Le Gouill, MD, PhD⁸, Marc André, MD¹⁰, Jehan Dupuis, MD¹¹, Catherine Thieblemont, MD, PhD¹², Emmanuel Bachy, MD, PhD¹³, Nicolas Daguindau, MD¹⁴, Franck Morschhauser, MD, PhD¹⁵, Sabine Tricot, MD¹⁶, Pierre Feugier, MD, PhD¹⁷, Anne Banos, MD¹⁸, Thierry Lamy De La Chapelle, MD, PhD¹⁹, Adrien Chauchet, MD²⁰, Emmanuel Gyan, MD, PhD²¹, Guillaume Cartron, MD, PhD²², Hassan Farhat, MD²³, Vincent Camus²⁴, Bernard Drenou, MD, PhD²⁵, Hacene Zerazhi, MD²⁶, David Sibon, MD, PhD²⁷, Emmanuelle Nicolas-Virelizier, MD²⁸, Caroline Delette, MD²⁹, Sylvia Snauwaert, MD³⁰, Nicole Straetmans, MD³¹, Richard Delarue, MD³², Marie Parrens, MD³³, Céline Bossard, MD³⁴, Laurence De Leval, MD³⁵, Philippe Gaulard, MD, PHD³⁶ and Gandhi Laurent Damaj, MD, PhD³⁷
<https://ash.confex.com/ash/2020/webprogram/Paper139224.html>

1139 – Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

Louise Bouard, MD in training¹, Catherine Thieblemont², Krimo Bouabdallah, MD³, Thomas Gastinne, MD⁴, Anne Moreau, MD⁵, Sibylle Masse⁶, Rémy Gressin, MD⁷, **Lucie Oberic, MD⁸**, Alexis Caulier, MD⁹, Emmanuel Gyan, MD, PhD¹⁰, Victoria Cacheux¹¹, Olivier Casanovas¹², Olivier Hermine¹³ and Steven Le Gouill, MD, PhD¹⁴
<https://ash.confex.com/ash/2020/webprogram/Paper139990.html>

2982 – Three-Dimensional Telomere Analysis Using Teloview® Technology Predicts the Response of Classic Hodgkin's Lymphoma Patients to First Line Therapy at Point of Diagnosis

Sherif Louis, PhD, BSc, MSc¹, Nathalie A Johnson, MD, PhD^{2,3}, Pierre Brousset, MD, PhD⁴, Olga Ludkovski, MSc⁵, Yulia Shifrin, PhD⁶, Sabine Mai, PhD⁶ and Hans Knecht, MD⁷
<https://ash.confex.com/ash/2020/webprogram/Paper140624.html>